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INTRODUCTION 
Caries and periodontal disease remain the most common oral infectious diseases in humans, despite the 
use of antibiotics, fluorides and other oral health agents. Antibiotic resistance acquired by oral micro-
organisms amplifies the need to develop innovative strategies for controlling plaque-related oral 
infections.1 Antimicrobial therapies for oral diseases have been in use for centuries, but have undergone 
rapid changes in recent years. New drug-delivery systems for common antimicrobials and novel agents 
to modulate the dental plaque/biofilm formation and maturation are currently emerging.2,3 Methods 
employed to deliver the antimicrobial agents to the site of oral infection include rinsing, irrigation, 
systemic administration and local application using sustained and controlled delivery devices.2,4 The 
efficiency of the drug-delivery system designed to target oral infections depends on its ability to deliver 
the drug at a bacteriostatic or bactericidal concentration and its ability to retain the medicament long 
enough to ensure adequate results. Since local drug delivery in the oral cavity may achieve these 
requirements, commercially available formulations such as minocycline microspheres, metronidazole 
and minocycline gels, chlorhexidine chips and doxycycline polymers are currently in use to treat 
periodontal disease.3–5 In these systems, polymers encapsulating an antibiotic or antiseptic are inserted 
or injected into the site of infection, where they degrade and release the active agent at the site of 
infection. Although some of these drug-delivery devices may achieve adequate bioavailability of 
antimicrobials to the site of infection, there are several disadvantages and limitations with these 
systems, as reported previously.3,4 Therefore small molecules with high affinity for enamel and the 
ability to deliver antimicrobials directly to the tooth and pellicle surface would be highly desirable. 
The selective adsorption of salivary proteins to the tooth surface forms the acquired enamel pellicle. 
These salivary molecules include mucins, α-amylase, PRG (proline-rich glycoprotein), PRPs (proline-rich 
proteins), cystatins, statherin and histatins. Pellicle-forming salivary proteins have a tooth-enamel-
binding domain,6,7 an antimicrobial region7–9 and a region that serves as a receptor for microbial 
colonization.10–13 The apatitic/tooth-surface-binding domain and an antimicrobial component could be 
linked by a biodegradable bond to efficiently deliver therapeutic agents intra-orally. Such a bifunctional 
hybrid molecule is expected to adhere to the tooth and pellicle surfaces uniformly, with a sustained 
release of the antimicrobial from the tooth surface inhibiting microbial colonization. 
The present paper describes the synthesis of two novel intra-oral antimicrobial delivery molecules, their 
substantivity and the antimicrobial release kinetics in clarified human whole saliva, and their toxicity to 
human cells. The antimicrobial activity of the molecules adsorbed on the tooth enamel mineral [HAP 
(hydroxyapatite)] surface against Candida albicans and Aggregatibacter actinomycetemcomitans, 
previously referred to as Actinobacillus actinomycetem-comitans, is also summarized in the present 
paper. 
EXPERIMENTAL 
Selection of peptides 
An analogue of the N-terminal fragment of statherin (Asp-Asp-Asp-Glu-Glu) with high affinity for the 
enamel surface6 has been selected as the carrier sequence. A 12-residue defensin-like peptide (Arg-Leu-
Cys-Arg-Ile-Val-Val-Ile-Arg-Val-Cys-Arg) with a disulfide bridge between the two cysteine residues was 
selected as the antimicrobial, since it has been shown to possess antimicrobial activity against several 
oral pathogens.14 The two components were linked through the side chain of a serine/aspartic acid 
residue to generate two bifunctional hybrid molecules with an ester and an anhydride bond between 
the two components respectively (Figure 1). The Cβ-carbon atoms of the serine and aspartic acid 
residues that link the carrier and the antimicrobial were 13C-labelled to monitor the release of the 
antimicrobial component from the carrier. 
  
Figure 1 Sequences of hybrid A and hybrid B 
The carrier and the antimicrobial components were linked through the side chain of the 13C-enriched amino acid 
(serine residue in hybrid A and aspartic acid residue in hybrid B) at the N-terminus of the carrier peptide. In human 
saliva, the biodegradable ester and anhydride bonds dissociate, causing a sustained release of the antimicrobial 
component. 
 
Among cathelicidins, defensins and histatins that are present in saliva, a defensin-derived peptide was 
selected. Defensins are salivary peptides as are histatins, since they are expressed and secreted by the 
salivary glands.15,16 Although histatins are potent antifungal peptides, they are antibacterial only at a 
much higher concentration than that for defensins.14,17,18 The antimicrobial peptide used in the hybrid 
molecule should be compatible in molecular size without hindering the enamel-binding efficacy of the 
carrier component. Although cathelicidin LL37 is a potent antimicrobial.19 its much larger size could 
mask the structure and function of the carrier molecule. Hence, a 12-residue defensin-like peptide was 
selected. 
General materials and methods 
Chemicals and solvents were of the highest purity available and used without further purification. Amino 
acid derivatives, Wang resin and NPN (N-phenyl-1-naphthylamine) were purchased from Sigma and 
Bachem. The 13C β-labelled serine and aspartic acid derivatives were purchased from Cambridge Isotope 
Laboratories. Calcein-AM (calcein-acetoxymethyl ester) and calcein were obtained from Molecular 
Probes. Hybrid peptides were synthesized using an Advanced Chemtech (ACT Model-90) peptide 
synthesizer. HPLC was carried out on a Rainin HPXL system interfaced to a Macintosh SE/30 computer, 
using a Rainin Dynamax C18 column (10 mm×250 mm) coupled with a guard column (10 mm×50 mm) 
and employing an acetonitrile/water (each containing 0.1% trifluoroacetic acid) linear gradient elution 
with a flow rate of 2.0 ml/min. The dried peptides were hydrolysed in sealed tubes for 24 h at 110 °C, 
using 6 M HCl in the presence of 1% phenol vapour, and amino acid analysis was performed on a 
PerkinElmer 420A derivatizer and analyser system. The amino acid sequence of the peptide (∼ 1 nmol) 
was checked by sequence analysis, using a PerkinElmer model 477A protein sequencer. FAB (fast atom 
bombardment) mass analysis was carried out on a VG Analytical ZAB 2-SE high-field mass spectrometer 
(M-Scan). A caesium ion gun was used to generate ions for the acquired spectra, which were recorded 
using a PDP 11-250J data system. Fluorescence studies were performed using a PerkinElmer 650-40 
fluorescence spectrophotometer. The HAP crystals with a specific surface area of 29±0.3 m2/g 
(Brunauer–Emmett–Teller nitrogen adsorption) were prepared as described previously6,20 and 
characterized by X-ray powder diffraction (Nicolet/Nic diffractometer with Stoe attachment, using a 
position-sensitive detector in the transmission mode). The calcium to phosphate molar ratio in the HAP 
crystal was 1.65±0.05. 
Synthesis of the bifunctional hybrid molecules (hybrid A and hybrid B) 
The synthesis of hybrid A and hybrid B was carried out as outlined in Supplementary Figures 1 and 2 
(http://www.BiochemJ.org/bj/409/bj4090601add.htm) by using the standard Fmoc (fluoren-9-
ylmethoxycarbonyl) and Boc (t-butoxycarbonyl) procedures.14,18,21 The cleaved peptide containing the 
acetamidomethyl protecting group on the two cysteine residues was deprotected and oxidized to form 
the disulfide, as described previously.14 Hybrid A and hybrid B were purified and tested for homogeneity 
as described in the Supplementary data (http://www.BiochemJ.org/bj/409/bj4090601add.htm). The 
bond between the carrier and the antimicrobial components was verified by FTIR (Fourier-transform 
infrared) spectroscopy. The presence of a disulfide bridge was verified by CD spectroscopy. 
Measurements of adsorption on HAP 
Adsorption experiments were carried out as described previously.6,22 HAP beads with a specific surface 
area of 29.2±0.3 m2/g were used for these experiments. Known amounts of peptides were equilibrated 
for 4 h with HAP crystallites (1×103 g) in a saturated solution (1 ml) at 37 °C and pH 7.4, using an ionic 
strength of 0.15 mol/l. Adsorption kinetics demonstrated that equilibrium was achieved in less than 4 h. 
To avoid bacterial degradation during adsorption, all peptide solutions were prepared with 0.1% 1,1,1-
trichloro-2-methyl-2-propanol. After adsorption, the HAP crystallites were separated from the 
supernatant solution by centrifugation at 250 g for 10 min. The peptide-adsorbed HAP crystallites were 
washed with saturated solution of HAP (2×1 ml). The peptide concentration in the supernatant solutions 
was determined by amino acid analysis and compared with the initial concentration. Amino acid analysis 
indicated that adsorbed molecules on HAP were not removed during washing. A parallel experiment 
performed in the absence of HAP crystals showed that peptide adsorption on the reaction vessels was 
negligible. 
FTIR measurements 
ATR-FTIR (attenuated total reflectance FTIR) spectra in solution were recorded on a Bio-Rad FTS-40 
spectrometer equipped with a deuterated triglycine sulfate detector and a Bio-Rad 3240-SPC computer 
for data acquisition and analysis. Spectra were recorded at 30 °C by using a Micro Circle cell (Spectra-
Tech) with a zinc selenide CIR (cylindrical internal reflectance) crystal in a stainless steel flow cell. A 
1024-scan interferogram was collected at a single beam with a resolution of 2 cm−1, using a peptide 
concentration of 0.5 mM. The spectrometer was continuously purged with dry air to eliminate water 
vapour adsorption. Solvent and sample spectra were recorded under identical conditions, and the 
difference spectra were obtained, as described previously.9 
CD spectroscopy 
CD measurements were carried out to verify the presence of the disulfide bond. An Aviv 62DS 
spectropolarimeter equipped with a thermostatic temperature controller and interfaced to an IBM 
microcomputer was used. CD spectra were recorded in a quartz cell of 0.05 nm path length at 30 °C, 
using a 1.0 nm bandwidth and a scanning rate of 10 nm/min with a wavelength step of 0.2 nm and a 
time constant of 2 s. Peptide dissolved in 10 mM sodium phosphate buffer at pH 7.2 at a concentration 
of 0.1 mM was used. 
NMR studies 
All 125-MHz 13C 1D (one-dimensional)-NMR spectra were recorded on a Varian Unity Inova 500 MHz 
spectrometer equipped with a SUN Sparckstation 20. A spectral width of 25157.2 Hz, a relaxation delay 
of 12 s and an acquisition time of 1.2 s were used. The proton decoupler was on only during the 
acquisition time and off during the delay time to eliminate the influence of NOE (nuclear Overhauser 
effect) effects on the intensity of the 13C resonances. Thus the signal intensity was dependent only on 
the quantity of the material for quantitative estimation.23,24 The 13C -NMR spectra of the hybrid 
molecules (500 μM) in 1 ml of clarified human whole saliva containing 5% 2H2O (37 °C, pH 7.2) at various 
intervals of time were recorded. Chemical shifts were referenced to tetramethylsilane (Me4Si) in a 
concentric capillary. 
Selection of test micro-organisms and growth conditions 
C. albicans is an opportunistic pathogen and is intimately associated with chronic oral infections which 
are increasing in the growing immunocompromised and aging populations worldwide. Moreover, in the 
sub-gingival flora of several adult periodontitis and AIDS patients, C. albicans has been detected.22,25 C. 
albicans also plays a significant role in DIS (denture-induced stomatitis), which is found in 20% of the 
aging population.26 C. albicans infection has been estimated to be as high as 60% among the denture-
wearing institutionalized subjects.27 
Defensins and defensin-like antimicrobial peptide have already been reported to be active against 
cariogenic Lactobacillus casei,28 Streptococcus mutans and periodontopathogenic Porphyromonas 
gingivalis and A. actinomycetemcomitans.14 To demonstrate and validate the controlled and sustained 
antimicrobial release from the hybrid molecules and its activity, C. albicans and A. 
actinomycetemcomitans were selected to represent a fungal and a bacterial organism respectively, both 
of which are associated with oral infectious diseases. 
A clinical isolate of C. albicans strain from a DIS patient was used. The identity of the clinical isolate was 
verified by the Yeast System (Flow Laboratories). Organisms were streaked on to Sabouraud Dextrose 
Agar plates (Difco) and maintained at 4 °C. One colony of C. albicans from this plate was inoculated into 
10 ml of yeast synthetic growth medium containing sucrose, salts and biotin, and incubated for 48 h at 
25 °C in a shaker rotating at 200 rev./min to bring yeast cells into the late exponential phase of growth. 
The cell morphology was determined by phase-contrast microscopy and found to be uniformly 
blastospores. Subcultures were done every 3 days by inoculating 100 μl of 3-day-old culture into 10 ml 
of fresh synthetic media. 
Candidacidal activity 
The candidacidal activity of the hybrid molecules was determined as a function of the release of the 
antimicrobial in clarified human whole saliva. The hybrid molecule was incubated with 1 ml of saliva 
buffer29 (the composition of which is shown in the Supplementary data) and 4 ml of clarified human 
whole saliva such that the final hybrid concentration was 100 μM kept at pH 7.2. The sample was 
divided into two and each portion was separately maintained at 37 and −5 °C, the latter to minimize the 
dissociation of ester/anhydride bond of the hybrid. Over time, aliquots of both samples (25 μl) were 
examined for candidacidal activity, as described previously.8,30 The assays were performed on stationary 
C. albicans cells in the presence or absence of the hybrid (25 μl), as described previously.30 Briefly, C. 
albicans cells were washed with 10 mM sodium phosphate buffer (pH 7.4) and resuspended at 1.8×105 
cells/ml. A cell suspension of 25 μl was mixed with 25 μl of hybrid in saliva and then incubated with 
shaking at 37 °C for 1.5 h. Control cultures were incubated with 25 μl of saliva and saliva buffer without 
the hybrid peptide. The reaction was stopped by the addition of 360 μl of yeast nitrogen base, and 40 μl 
of the suspension was spread on to Sabouraud dextrose agar plates and incubated for 48 h at 37 °C. 
Candidacidal assays were performed in duplicate or triplicate. Loss of viability was calculated as {1–
[(number of colonies from suspensions with hybrid)/(number of colonies from suspension with no 
hybrid)]}×100. 
Measurement of the loss of microbial cell membrane integrity 
A. actinomycetemcomitans strain Y4 was maintained on tryptic soy agar plates containing yeast extract 
(0.5%). For liquid culture, cells were grown in the respective broths. All experiments were carried out in 
an anaerobic chamber (85% N2, 10% H2 and 5% CO2; Coy Laboratory Products) and the purity of the 
bacterial strain was confirmed routinely as described previously.7,14 
The efficacy of peptides to induce loss of cell membrane integrity has been well correlated with their 
microbicidal activity.22,30,31 Hence, the efficacy of the hybrid-bound HAP surface in inducing disruption of 
cell membrane permeability was determined as a measure of microbicidal activity. Calcein-AM and NPN 
were used as fluorescent probes to examine C. albicans and A. actinomycetemcomitans membrane 
permeability respectively. The peptide-induced leakage of a fluorescent probe (calcein-AM) 
incorporated within C. albicans membranes, and the peptide-induced incorporation of the membrane-
excluded probe (NPN) into bacterial membranes, were monitored. 
Measurement of the loss of C. albicans cell membrane integrity 
C. albicans cells were loaded with the fluorescent probe calcein-AM. The calcein-AM is non-fluorescent 
within the cell. The cellular esterases convert the ester into an acid, the fluorescence of which was 
quenched within the cell membrane. The fluorescence was de-quenched when calcein leaks into the 
extracellular environment. Peptide-induced leakage of calcein was monitored by measuring the de-
quenching of fluorescence at 520 nm by exciting the system at 495 nm. The assay was performed as we 
described previously.22,30 C. albicans cells (3 days old) were washed twice with 20 ml of PBS and the 
concentration was adjusted to 107 cells/ml. Calcein-AM (5 μl of 1 mM) was added to 1 ml of cells. The 
cells were incubated for 4 h at room temperature (25 °C) and then washed extensively with 10 mM PBS 
to remove unincorporated calcein-AM. For the assay, 100 μl of the calcein-AM-loaded cells (105 
cells/ml) were mixed with 50 mg of hybrid-adsorbed HAP beads. The final volume in the cuvette was 
1 ml. The fluorescence intensity (Fa) was measured at 520 nm using a λex of 495 nm at regular intervals 
of time for 10 h. The cell suspension was stirred gently for 10 s after each measurement and at regular 
intervals to ensure cell–bead contact. The fluorescence intensity at 520 nm of cells and clean untreated 
HAP beads after 15 min was taken as the background fluorescence (Fb). The total fluorescent content of 
the cell was determined by incubating the cells at 100 °C for 5 min (Ft). The minimal non-specific leakage 
of fluorescence from cells alone was determined after 6 h and subtracted from that obtained from cells 
and hybrid-bound HAP. The percentage release of calcein=[(Fa−Fb)/Ft]×100. The fluorescence intensity 
measurement of cells and free HAP beads was used as the control. 
Assessment of the loss of bacterial membrane integrity 
The membrane permeability induced by the released antimicrobial from the hybrid-adsorbed HAP was 
assessed by the extent the antimicrobial permeabilized the outer bacterial membrane. This was 
determined by using the neutral hydrophobic probe NPN. Antimicrobial peptides bind to 
lipopolysaccharide, displacing the native bivalent cations and disrupting the outer membrane 
permeability. NPN is excluded from an intact outer membrane.32,33 However, when the permeability of 
the bacterial outer membrane is disrupted, NPN enters the membrane, resulting in fluorescence. Briefly, 
1 ml of mid-exponential-phase A. actinomycetemcomitans strain Y4 cell suspension was incubated with 
5 μl of 1 mM NPN and then treated with 50 mg of hybrid-bound HAP. Fluorescence intensity was 
measured at 420 nm using a λex of 340 nm at regular intervals of time for 10 h. The cell suspension was 
stirred gently for 10 s after each measurement and at regular intervals to ensure cell–bead contact. The 
percentage intake of NPN was calculated, as described in the previous section, from the formula: 
percentage intake of NPN=[(Fa−Fb)/Ft]×100. The fluorescence intensity measurement of cells and free 
HAP beads was used as the control. 
Isolation of human erythrocytes 
The leakage of Hb from human erythrocytes was monitored by using standard procedures.34 Briefly, 
blood obtained by venipuncture from normal healthy volunteers with informed consent was collected in 
lithium-heparinized tubes, centrifuged at 450 g at 4 °C for short times (5 min), and the plasma and buffy 
coat were removed. Erythrocytes were then washed three times with PBS at 4 °C before being dispersed 
in PBS, counted in a haemocytometer and used on the day of harvesting. After washing, cells were 
resuspended in PBS and adjusted to give a final concentration of 1×108 cells/ml. Ouabain (10−6 M) was 
added to the final cell suspension to inhibit the membrane-bound Na+/K+ ATPase pump. For the 
determination of leakage of Hb, 2 ml of cell suspension (5×107cells/ml) in PBS was incubated for 1 h at 
37 °C with the test material. After the incubation, the cells were centrifuged at 1500 g for 5 min and 
washed three times with PBS for 10 s. The supernatant was collected and the degree of haemolysis was 
determined by comparing the Hb concentration in the supernatant with that in the original cell 
suspension by measuring the absorbance (A) at 540 nm; 0% haemolysis and 100% haemolysis were 
determined by suspending cells in PBS and 1% Triton X-100 respectively. Salivary histatin 5 and melittin 
were used as negative and positive controls respectively. 
Human GEC and GFC culture 
Human GECs (gingival epithelial cells) and GFCs (gingival fibroblast cells) were cultured using an explant 
technique according to previously described procedures with slight modifications.35,36 Tissue specimens 
were derived from histologically normal areas of gingiva collected during elective periodontal/oral 
surgical procedures with the consent of otherwise-healthy patients. The GECs were isolated by using 
standard procedures.35,37 After collection, gingival tissue specimens were placed in sterile PBS 
supplemented with penicillin, streptomycin and amphotericin B. The tissues were then incubated with 
0.4% dispase (BM Biochemicals) overnight at room temperature. The surface epithelium was separated, 
minced and placed in sterile PBS containing trypsin (0.55%) and EDTA (0.53 mM) to dissociate the intact 
epithelium into single cell suspensions. Cells were collected by centrifugation and cultured in serum-
free, sterile keratinocyte basal medium supplemented with epidermal growth factor (0.1 ng/ml), insulin 
(5 μg/ml), cortisol (0.5 μg/ml), CaCl2 (0.15 mM), bovine pituitary extract (20 μl/ml), gentamicin 
(50 μg/ml) and amphotericin B (50 ng/ml) (KGM; Clonetics Corp.). Tissue culture dishes (100 mm) pre-
coated with murine collagen type IV (5 mg/ml) were seeded with stock cultures of cells which had been 
stored in liquid nitrogen, and incubated at 37 °C in an air/5% CO2 atmosphere until confluent growth 
was attained. Cells were removed from the dishes by trypsin treatment (1×trypsin–EDTA; Fisher 
Scientific) for 5 min at room temperature. The cells were harvested by centrifugation at 800 g for 5 min 
and resuspended in KGM medium. Cell cultures from the second and third passages were used for 
testing. After separating the epithelium, GFCs were cultured by the procedure reported previously.36 
Tissues were minced using sterile techniques and washed twice with PBS supplemented with antibiotics 
(100 units/ml penicillin, 100 mg of streptomycin and 0.25 μg/ml fungizone). Explants were placed in 60-
mm Petri dishes and maintained in Dulbecco's modified Eagle's medium supplemented with 10% (v/v) 
FBS (fetal bovine serum) and antibiotics, as described above. Cultures were maintained at 37 °C in a 
humidified atmosphere of 5% CO2 and 95% air. Confluent cells were detached by treatment with 0.25% 
trypsin and 0.05% EDTA for 5 min, and aliquots of cells were subcultured with the same medium. Cell 
cultures from the third to eighth passages were used for investigation. 
Cytotoxicity assay 
The effect of hybrid molecules on human cells was determined by the colorimetric assay, which is based 
on the ability of live but not dead cells to reduce the MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-
tetrazolium bromide] to a blue formazan product.38,39 The MTT assay in a 96-well plate was performed 
to monitor cell survival and proliferation. MTT assay was carried out by measuring dehydrogenase 
activity as described previously,40,41 with minor modifications. Briefly, 1×104 cells per well were seeded 
on to a 96-well plate and left overnight. Serial dilution of various extracts (6.25, 12.5, 25, 50 and 75 μl, 
prepared in the same solvent) in 100 μl volume was added, and cells were treated for 24 h. After 
treatment, 50 μl of MTT solution (1 mg/ml in PBS) was added to each well and incubated for another 4 h 
at 37 °C. DMSO (150 μl) was added to each well and the plates were shaken to ensure the dissolution of 
crystals. Culture viability was determined by measuring, spectrophotometrically, the reduced MTT in a 
dual-beam microtitre plate reader (Molecular Devices tunable microplate reader) at 590 nm with a 
630 nm reference. Four wells were used for each experimental group. 
RESULTS 
Synthesis of hybrid peptides 
The synthetic scheme and the purification procedure yielded hybrid A and hybrid B in the pure state 
(100%). The percentage yield was 96% with the acetamidomethyl protecting group on the two cysteine 
residues. The formation of intra-molecular disulfide between the two cysteine residues was 
accomplished in a very dilute solution. After evaporation and purification, the percentage yield of the 
final product was 65%. 
Analytical HPLC analysis verified the purity of the hybrid peptides. Amino acid analyses were consistent 
with the amino acid composition of the respective hybrid molecules. Amino acid sequence analyses 
verified the presence of amino acid residues corresponding to the carrier and antimicrobial sequences. 
The FAB mass spectra showed intense molecular ion clusters centred at m/z 2275 and 2303 that are 
consistent with the molecular masses of hybrid A and hybrid B respectively. The molecular ions are also 
consistent with the presence of the disulfide bridge and the 13C β-enriched amino acid residue that 
connects the antimicrobial and the carrier components.42,43 The CO stretching band in the FTIR spectra 
that occurred between 1725 and 1740 cm−1 verified the presence of an ester bond in hybrid A, whereas 
the two bands between 1800 and 1900 cm−1 separated by approx. 65 cm−1 showed the carbonyl stretch 
corresponding to the anhydride linkage in hybrid B.44 Hybrid A and hybrid B exhibited a weak negative 
n–σ* CD band (Supplementary Figure 3 at http://www.BiochemJ.org/bj/409/bj4090601add.htm) at 
approx. 265–270 nm (molar ellipticity≅−5000–6000 deg·cm2·dmol−1), characteristic of the disulfide 
bond that is normally observed between 240 and 300 nm.45 Similar CD bands have been observed and 
reported for oligopeptides containing a disulfide bridge.8,14,18 
Adsorption of hybrid molecules to the HAP surface 
The adsorption, Q (mol/m2), of hybrids on the HAP surface measured at various equilibrium 
concentrations, C (molar), was determined and compared with that of salivary statherin, as described 
previously.46 The affinity coefficient, K (litre/mol), and the maximum number of adsorption sites, N 
(mol/m2), calculated by using the Langmuir equation,46 C/Q1=KN+C/N, are provided in Table 1. Hybrid A 
and hybrid B exhibited high relative affinity for HAP with the K values of 9.0±1.8 and 9.2±1.7 litres/mol 
respectively (Table 1). The extent of adsorption on HAP and the affinity coefficients were quite 
comparable with those of salivary statherin (Table 1), which has been reported to have the highest 
affinity for the HAP surface.6 The affinity coefficient K (litre/mol), and the maximum number of 
adsorption sites, N (mol/m2), observed for salivary statherin (Table 1) were consistent with those 
reported previously.6,20 Affinity coefficient values observed for hybrid A and hybrid B suggested that 
both the molecules could efficiently bind to the tooth enamel mineral surface. Even though salivary 
statherin and the hybrid molecules have comparable affinity coefficients, hybrid A and hybrid B showed 
a higher maximum adsorption, suggesting that a greater number of smaller molecules were able to 
interact per unit surface area of HAP than the longer parent molecule. The antimicrobial at the N-
terminus of the carrier did not seem to alter the affinity for HAP surface. 
Table 1 Langmuir parameters for salivary statherin and hybrid molecules 
K and N values observed for salivary statherin are consistent with those reported previously.6,20 
Peptide K×10−6 (litre/mol) N×106 (mol/m2) 
Statherin  11.2±1.1 0.44±0.1 
Hybrid A 9.0±1.8 1.9±0.1 
Hybrid B  9.2±1.7 2.0±0.2 
 
The adsorption of salivary statherin and its fragments on HAP mineral is a real equilibrium system as 
reported previously.6,20 As mentioned in the Experimental section, previous adsorption experiments 
showed that equilibrium was achieved in less than 4 h.6,20 The susceptibility of the ester and anhydride 
linkages in hybrid A and hybrid B respectively could influence the equilibrium. However, 13C -NMR data 
reported in the present paper suggested that the dissociation of the hybrid was slow and expected to be 
minimal within 4 h. Hence, the affinity constant values determined were well within the error limits. 
Kinetics of the antimicrobial release in human whole saliva 
The Cβ-carbon atoms of the serine and aspartic acid residues that connected the carrier and the 
antimicrobial in hybrid A and hybrid B respectively were enriched with 13C to monitor the release of the 
antimicrobial by 13C -NMR spectroscopy. Since the natural abundance of 13C is only 1.1%, the resonance 
intensities of all other carbons merged with the noise levels except the 13C β-carbons of the 13C -enriched 
serine and aspartic acid residues. The integrated intensity of the 13C β resonances was monitored to 
determine the extent of release of the antimicrobial in saliva. Quantitative estimation of molecules 
based on the integrated intensity of 13C resonance has been well documented.23,24 The 13C -NMR spectra 
of hybrid A and hybrid B (each 500 μM) in clarified human whole saliva recorded at 37 °C and pH 7.2 at 
various intervals of time are provided in the Supplementary data. As described in the Supplementary 
data, the integrated intensity of CβH2OH and CβH2COOH over time was used to determine the kinetics of 
release of the antimicrobial from hybrid A and hybrid B respectively (see Supplementary Figure 4 at 
http://www.BiochemJ.org/bj/409/bj4090601add.htm). As described in Figure 2(A), the increase in the 
integrated intensity of CβH2OH plotted over time suggested that 50% of hybrid A dissociated in clarified 
human whole saliva over a period of 32 h, indicating that a sustained release of the antimicrobial could 
be achieved over a period of more than 60 h. The increase in the integrated intensity of CβH2COOH over 
time suggested that 50% of hybrid B dissociated over a period of 20 h (Figure 2A), indicating that the 
antimicrobial could be released in saliva over a period of 40 h. The results suggested that in clarified 
human whole saliva, hybrid A and hybrid B could substantially release the antimicrobial over a period of 
60 and 40 h respectively. Under similar conditions, the anhydride linkage between the carrier and the 
antimicrobial released the antimicrobial faster than the ester bond in hybrid A (Figure 2A). 
 
Figure 2 Kinetics of the release of the antimicrobial from the carrier 
(A) The dissociation of the ester and anhydride bonds in hybrid A and hybrid B respectively as determined by the 
increase in the integrated intensity of the 13C resonances of CβH2OH and CβH2COOH in hybrid A and hybrid B 
respectively over time. Peptides (500 μM) were dissolved in 1 ml of human clarified whole saliva containing 5% 
2H2O at 37 °C and pH 7.2. (B) Percentage loss of viability of C. albicans (DIS) induced by hybrid A and hybrid B in 
clarified human whole saliva maintained at −5 °C and at 37 °C over time. Hybrid molecules were dissolved in 1 ml 
of saliva buffer and 3 ml of clarified human whole saliva (at pH 7.2 and a peptide concentration of 100 μM). 
Samples were maintained separately at 37 and −5 °C. Aliquots were examined for candidacidal activity over time as 
described in the Experimental section. Results are means±S.D. for duplicate determinations from three different 
experiments. 
Candidacidal activity of hybrid molecules as a function of the antimicrobial release 
The candidacidal activity of hybrid A and hybrid B in clarified human whole saliva (100 μM) maintained 
at 37 °C and −5 °C is provided in Figure 2(B). The loss of cell viability of the hybrid molecules maintained 
at 37 °C was found to be approx. 20% at the initial time (Figure 2B). This might be due to the intact 
hybrid molecule. The increase in the candidacidal activity was not significant for up to nearly 1 h. After 
this period, the percentage loss of viable cells increased over time, and 90% killing was achieved within 
5 h for hybrid A (Figure 2B) and 3 h for hybrid B. However, for samples maintained at −5 °C, the 
percentage loss of viable cells did not increase with time, suggesting that the dissociation of the hybrid 
molecules was minimal at low temperature and reflected the activity of the intact molecule, since the 
dissociation of the ester and anhydride bonds was expected to be minimal at this temperature. The 
results suggested that hybrid A and hybrid B released the antimicrobial over time in human saliva at 
37 °C and enhanced the candidacidal activity (Figure 2B). The increase in the candidacidal activity over 
time was consistent with the 13C -NMR data and the kinetics of the release of the antimicrobial from the 
hybrid molecules (Figure 2A). 
Candidacidal activity of the hybrid-adsorbed HAP surface 
Hybrid-adsorbed HAP beads obtained by equilibration with the hybrid concentration (4.0×10−5 mol/l) 
were used to determine the candidacidal activity of peptides in a bound state on the mineral surface. 
Incubation of calcein-AM-loaded C. albicans with the hybrid-adsorbed HAP beads caused a steady 
increase in fluorescence intensity over time measured at 520 nm, when excited at 490 nm. The increase 
in fluorescence intensity was measured and the percentage release of the fluorescent probe from the C. 
albicans membrane over time is shown in Figure 3(A). The increase in fluorescence intensity was not 
significant for 0.5 h. After this time, a steady significant enhancement in fluorescence intensity was 
observed for hybrid A- and hybrid B-adsorbed HAP surfaces, as compared with that of the free HAP 
beads (Figure 3A). The result suggested the leakage of the fluorescent probe calcein-AM from C. albicans 
membrane, as a consequence of the increased membrane permeability and the damage caused by the 
antimicrobial component of the hybrid molecules. Collectively, the results suggested that the 
antimicrobial component of the hybrid was released over time from the HAP surface disrupting the C. 
albicans membrane. 
 
Figure 3 Candidacidal activity of hybrid-molecule-adsorbed HAP surface 
(A) Candidacidal activity as determined by the percentage release of calcein from C. albicans membrane. Calcein 
release induced by the antimicrobial released from (a) hybrid A-adsorbed HAP surface, (b) hybrid B-adsorbed HAP 
surface and (c) control HAP surface. (B) Bactericidal activity of hybrid-molecule-adsorbed HAP surfaces as 
determined from the percentage intake of NPN into A. actinomycetemcomitans cell membrane. The percentage 
intake of NPN induced by the antimicrobial released from (a) hybrid A-adsorbed HAP surface, (b) hybrid B-
adsorbed HAP surface and (c) control HAP surfaces. Experiments were carried out at 37 °C and pH 7.2. Results are 
means±S.D. for duplicate determinations from three different experiments. 
Bactericidal activity of the hybrid-adsorbed HAP surface 
Hybrid-adsorbed HAP beads were also used to determine the bactericidal activity against A. 
actinomycetemcomitans. The efficacy of the antimicrobial component of the hybrid to permeabilize the 
bacterial membrane was determined by using the fluorescent probe NPN. Incubation of A. 
actinomycetemcomitans cells with the hybrid-adsorbed HAP resulted in an increased fluorescence over 
time. The increase in fluorescence intensity was found to be slow for the initial 0.5 h. After this period, a 
steady increase in fluorescence was observed over time for HAP surfaces coated with hybrid A and 
hybrid B. The percentage intake of NPN into the bacterial membrane calculated from the fluorescence 
intensity over time is shown in Figure 3(B). As compared with the control HAP, which has no hybrid on 
its surface, hybrid A- and hybrid B-adsorbed HAP surfaces showed a significant increase in the 
percentage intake of NPN (Figure 3B). The result suggested the incorporation of NPN into the bacterial 
membrane due to increased membrane permeability caused by the antimicrobial component released 
from the respective HAP surface. Collectively, the results suggested that the antimicrobial component of 
the hybrid was released over time from the HAP surface causing the A. actinomycetemcomitans cell 
membrane to permeabilize (Figure 3B). 
Hybrid-induced leakage of Hb 
The percentage release of Hb as a function of molar concentration of peptides is described in Figure 4. 
Hybrid A and hybrid B exhibited minimal haemolysis over the concentration range of 0–250 μM, 
suggesting that these molecules did not permeabilize human erythrocytes, although they exhibited 
marked influence on microbial cell membranes. Melittin is known to permeabilize human erythrocytes 
and it exhibited a significant increase in percentage haemolysis (Figure 4). Salivary histatin 5, which is 
expected to be non-toxic, appeared to exhibit some haemolytic activity at a high concentration. 
However, the hybrid molecules did not affect human erythrocyte membrane up to a concentration of 
250 μM. 
 Figure 4 Effect of hybrid molecules on human erythrocytes 
The leakage of Hb was determined by measuring the absorbance at 540 nm. The percentage haemolysis was 
determined at 37 °C for various peptide concentrations; 0% haemolysis and 100% haemolysis were determined by 
suspending the cells in PBS and 1% Triton X-100 respectively. Salivary histatin 5 and melittin were used as the 
negative and positive controls respectively. Results are means±S.D. for duplicate determinations from three 
different experiments. 
 
Effects of hybrids on human GECs and GFCs 
The MTT assay was used to determine the viability and proliferation of human GECs and GFCs. When 
these cells were exposed to hybrid A or hybrid B (at 62.5 and 250 μM), the effects on cell viability and 
proliferation over time are described in Figure 5. Chlorhexidine, which is currently used as the gold 
standard for oral antiseptics, was examined as the positive control. Even at the concentration of 
250 μM, neither of the hybrid molecules affected cell viability over a period of more than 72 h. In 
addition, cell proliferation was not affected by the presence of the hybrid molecules (Figure 5). On the 
other hand, even at a much lower concentration (125 μM), cell viability and growth were significantly 
affected, when human GECs and GFCs were exposed to chlorhexidine which was consistent with 
previous reports.47,48 The results suggested that hybrid A and hybrid B are not toxic to human GECs and 
GFCs. 
 Figure 5 Effect of hybrid molecules on human GECs and GFCs 
Hybrid molecules' effect on human GECs (A) and human GFCs (B). Cell viability and proliferation were monitored 
over time using the MTT assay, as described in the Experimental section by measuring spectrophotometrically the 
reduced MTT in a dual-beam microtitre plate reader at 570 nm with a 650 nm reference. The effect of the 
presence of (a) the culture medium (control), (b) chlorhexidine, (c) hybrid A at 62.5 μM, (d) hybrid A at 250 μM, (e) 
hybrid B at 62.5 μM (f) or hybrid B at 250 μM on cell viability and proliferation is shown. 
DISCUSSION 
Tooth enamel-binding peptides as carriers for intra-oral delivery of therapeutics 
The fragment (Asp-Asp-Asp-Glu-Glu) of statherin could be used as a carrier for intra-oral delivery of 
therapeutic agents. The oral physiological environment could greatly induce the release of the 
antimicrobial from the tooth surface and in saliva due to the susceptibility of the ester and anhydride 
bonds. In salivary defence molecules, the antimicrobial sequences are linked by the secondary 
amide/peptide bond and the release of the antimicrobial requires specific salivary proteolysis. However, 
microbial invasion results in the inactivation of salivary proteolysis and the secretion of natural 
antimicrobials.49 Therefore, it becomes necessary to deliver antimicrobials intra-orally and to induce a 
sustained release of the antimicrobial from the tooth surface and in saliva. The ester/anhydride bond in 
the hybrid might cause a sustained release of the antimicrobial over time without the involvement of 
any specific enzyme. 
Molecules designed to target oral pathogens should be stable in saliva and the antimicrobial component 
should be released gradually over time to combat microbial colonization. Hybrid A and hybrid B 
appeared to meet these criteria in vitro, as described in the 13C -NMR studies (Figure 2A) The high 
affinity coefficients observed for hybrid A and hybrid B (Table 1) indicated that they could be 
substantially adsorbed on the tooth surface when used topically as a mouth rinse. Hybrid molecules did 
not appear to be toxic to human cells, including human erythrocytes (Figures 4 and 5). 
Intra-oral delivery of antimicrobials 
Caries, gingivitis and periodontal disease still remain the most common infections in humans. The major 
limitations of the currently available local drug-delivery systems include: (i) adverse events such as 
dental or gingival pain, soreness, discomfort and sensitivity; (ii) difficulty in inserting or injecting the 
drug-delivery device around all teeth; (iii) retention of the device at the tooth surface or within the 
periodontal pockets for a sufficient length of time; (iv) toxic effects and bacterial resistance induced by 
the conventional antibiotics used in the current devices; and (v) requirement for professional application 
and high cost.2–4 In contrast with the existing formulations that have little to no affinity for the tooth or 
pellicle surface, the bifunctional hybrid molecules could adhere on the tooth and pellicle surfaces 
uniformly due to the high affinity for the tooth enamel surface, thereby inhibiting microbial 
accumulation. In addition, these bifunctional molecules would decrease the limitations and discomfort 
associated with the currently available local drug-delivery devices. 
These two bifunctional hybrid molecules could serve as efficient intra-oral antimicrobial delivery 
systems that may: (i) get adsorbed quickly with high affinity on the tooth and pellicle surfaces; (ii) 
provide a sustained release of an antimicrobial induced by the oral physiological environment; (iii) block 
the binding sites on tooth and pellicle surfaces to inhibit bacterial recolonization promoted by the 
adsorbed salivary proteins; (iv) disrupt bacterial cell membranes leading to cell death due to the 
presence of the selective natural antimicrobial agent, thereby reducing drug resistance among oral 
pathogens, and (v) eliminate the discomfort and other disadvantages of the currently available drug-
delivery devices. Unlike the local delivery devices that require professional insertion or injection, the 
hybrids can be easily applied and replenished by rinsing, brushing or irrigation. They could also be used 
professionally for site-specific applications to sub-gingival areas, if required. 
Although new drug-delivery systems such as nanoparticles, microbubbles, mucoadhesives and hydrogels 
have emerged in recent years, they have not yet been fully developed for intra-oral delivery of 
antimicrobials.3 The results presented in the present paper demonstrate the proof of concept for a novel 
intra-oral delivery system and validate the previously proposed defence mechanism that exists in the 
oral cavity.7,13 However, further studies are required to validate the in vivo efficacy of intra-oral 
antimicrobial delivery and safety of these hybrid peptides. 
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